Shionogi ADR Short Interest Tumbles 97.4% in September
Shionogi's unsponsored ADR saw short interest fall 97.4% to 33,851 shares by Sept. 30, from 1,297,436 shares two weeks earlier. Short interest was about 0.0% of shares outstanding, with a days-to-cover ratio of 0.3 days. The company posted quarterly EPS of $0.36, beating the $0.18 consensus, and revenue of $1.04 billion also exceeded expectations; the ADR traded at $8.70 and had an average Buy rating after upgrades from Goldman Sachs and Jefferies.
Shionogi’s unsponsored ADR, traded over the counter under SGIOY, saw short interest drop to 33,851 shares by Sept. 30 from 1,297,436 two weeks earlier. That equaled roughly 0.0% of shares outstanding and 0.3 days to cover, based on average daily volume of 130,379 shares.
The Osaka-based pharmaceutical firm, founded in 1878, focuses on infectious diseases and central nervous system disorders. Its quarterly EPS of $0.36 beat the $0.18 consensus, and revenue of $1.04 billion topped the $970.69 million estimate. Goldman Sachs and Jefferies upgraded the ADR to strong buy; the average rating is Buy, with the ADR at $8.70.
A sharp decline in short interest may signal less bearish positioning, potentially reducing trading volatility for ADR holders. Better-than-expected results and analyst upgrades could support investor confidence, which may help the company fund research. Patients and employees might benefit indirectly if drug development and commercialization remain stable, though market moves alone do not determine access or outcomes.